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AbstrAct
Objective
To estimate benefits and harms of different colorectal 
cancer screening strategies, stratified by (baseline) 
15-year colorectal cancer risk.
Design
Microsimulation modelling study using 
MIcrosimulation SCreening ANalysis-Colon (MISCAN-
Colon).
setting
A parallel guideline committee (BMJ Rapid 
Recommendations) defined the time frame and 
screening interventions, including selection of 
outcome measures.
POPulatiOn
Norwegian men and women aged 50-79 years with 
varying 15-year colorectal cancer risk (1-7%).
cOmParisOns
Four screening strategies were compared with no 
screening: biennial or annual faecal immunochemical 
test (FIT) or single sigmoidoscopy or colonoscopy at 
100% adherence.
main OutcOme measures
Colorectal cancer mortality and incidence, burdens, 
and harms over 15 years of follow-up. The certainty 
of the evidence was assessed using the GRADE 
approach.
results
Over 15 years of follow-up, screening individuals 
aged 50-79 at 3% risk of colorectal cancer with 
annual FIT or single colonoscopy reduced colorectal 
cancer mortality by 6 per 1000 individuals. Single 
sigmoidoscopy and biennial FIT reduced it by 5 per 
1000 individuals. Colonoscopy, sigmoidoscopy, and 
annual FIT reduced colorectal cancer incidence by 
10, 8, and 4 per 1000 individuals, respectively. The 
estimated incidence reduction for biennial FIT was 1 
per 1000 individuals. Serious harms were estimated 
to be between 3 per 1000 (biennial FIT) and 5 per 
1000 individuals (colonoscopy); harms increased 
with older age. The absolute benefits of screening 
increased with increasing colorectal cancer risk, while 
harms were less affected by baseline risk. Results 
were sensitive to the setting defined by the guideline 
panel. Because of uncertainty associated with 
modelling assumptions, we applied a GRADE rating of 
low certainty evidence to all estimates.
cOnclusiOns
Over a 15 year period, all screening strategies may 
reduce colorectal cancer mortality to a similar extent. 
Colonoscopy and sigmoidoscopy may also reduce 
colorectal cancer incidence, while FIT shows a smaller 
incidence reduction. Harms are rare and of similar 
magnitude for all screening strategies.
Introduction
Colorectal cancer is a public health issue, with an 
estimated 1.4 million new cases and 700 000 deaths 
worldwide in 2018.1 Screening is intended to reduce 
colorectal cancer incidence and mortality, and its 
effectiveness has been demonstrated in randomised 
controlled trials of guaiac faecal occult blood testing 
(gFOBT) and sigmoidoscopy.2-11 Colonoscopy is likely 
to be at least as effective as sigmoidoscopy since it 
reaches the whole large bowel, whereas sigmoidoscopy 
reaches only the distal part of the large bowel. Faecal 
immunochemical testing (FIT) is likely to be at least 
as effective as gFOBT, since both tests detect blood in 
stools, and FIT demonstrates higher sensitivity and 
specificity.12 However, because of the lack of published 
evidence from randomised trials for colonoscopy and 
For numbered affiliations see 
end of the article.
Correspondence to:  
M Buskermolen 
m.buskermolen@erasmusmc.nl  
(ORCID 0000-003-3417-1994)
Additional material is published 
online only. To view please visit 
the journal online.
cite this as: BMJ 2019;367:l5383 
http://dx.doi.org/10.1136/bmj.l5383
Accepted: 14 September 2019
WhAt Is AlreAdy knoWn on thIs topIc
Randomised trials with 15 or more years of follow-up have shown that 
sigmoidoscopy and guaiac faecal occult blood test (gFOBT) screening reduce 
colorectal cancer mortality
Colonoscopy and faecal immunochemical test (FIT) are increasingly used for 
colorectal cancer screening, but there are no published data from randomised 
trials on the relative effectiveness of the different screening strategies
Although risks and benefits differ across individuals, there is limited evidence 
for individualised screening recommendations. Basing screening on individual 
cancer risk, determined in large part by age and sex, may be desirable
WhAt thIs study Adds
This modelling study found that, over a 15 year period, colorectal cancer 
mortality reduction may be very similar with a single colonoscopy or 
sigmoidoscopy, or annual or biennial FIT. Colonoscopy and sigmoidoscopy may 
result in similar reductions in colorectal cancer incidence, while the effect of FIT 
on incidence may be smaller or absent
At a baseline cancer risk of 3%, MISCAN-Colon estimates for 1000 individuals 
over 15 years are:
Colorectal cancer deaths prevented: colonoscopy 6, sigmoidoscopy 5, annual 
FIT 6, biennial FIT 5
Colorectal cancer cases prevented: colonoscopy 10, sigmoidoscopy 8, annual 
FIT 4, biennial FIT 1
Harms were similar across screening strategies, with serious colonoscopic 
complications of <5 per 1000 at highest risk levels
Screening benefits and harms may increase as risk of colorectal cancer 
increases; benefits more so than harms
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FIT screening, it is not known if they are more effective 
than gFOBT and sigmoidoscopy.13
Despite its benefits, colorectal cancer screening can 
be burdensome, and colonoscopy is associated with 
rare but serious complications. In addition, screening 
performance depends on the baseline risk of cancer 
for individuals. Few studies and guidelines have 
incorporated how baseline risk affects the balance 
between benefits, burden, and harms of screening in 
the past.
To elucidate these issues, we undertook micro-
simulation modelling as part of the BMJ Rapid 
Recommendations project, a collaborative effort from 
the MAGIC research and innovation programme (www.
magicproject.org) and The BMJ. The aim of the Rapid 
Recommendations is to respond to new, potentially 
practice changing, evidence and provide trustworthy 
practice guidelines in a timely manner. The BMJ 
Rapid Recommendations project for colorectal cancer 
screening was triggered by recent updates from three 
large randomised trials on sigmoidoscopy screening 
with follow-up data of 15 years or longer.3 5 14 In light 
of this new evidence, we addressed the potential 
benefits and harms of colorectal cancer screening 
with annual or biennial FIT or a single sigmoidoscopy 
or colonoscopy in the time frame of 15 years. This 
work informed the parallel guideline published in 
a multilayered electronic format on bmj.com and 
MAGICapp. Box 1 shows the articles and evidence 
linked to this Rapid Recommendation.
Methods
At the request of the guideline panel (Helsingen et 
al15), we applied the Microsimulation Screening 
Analysis-Colon (MISCAN-Colon) model to simulate 
15 years of follow-up of population cohorts aged 50-
79 years. We estimated the benefits, burden, and 
harms of the following four screening strategies: 
annual FIT, biennial FIT, a single sigmoidoscopy, and 
a single colonoscopy. We compared the four screening 
strategies with each other and with no screening. We 
performed the analyses stratified by different levels 
of baseline colorectal cancer risk. Additionally, we 
determined screening benefits for men and women 
separately, and screening harms for different age 
groups, as requested by the panel.
miscan-colon model
MISCAN-Colon is a well established microsimulation 
model for colorectal cancer.17 18 In brief, MISCAN-Colon 
simulates life histories of a large group of individuals 
from birth to death. In addition, the model simulates 
the development of colorectal cancer through the 
adenoma carcinoma sequence. As each simulated 
person ages, one or more adenomas may develop. 
These adenomas can progress in size increasing from 
small (≤5 mm) to medium (6–9 mm) to large (≥10 mm). 
Some adenomas can develop into preclinical cancer, 
which may progress through cancer stages I to IV. At 
any time during the development of the disease, the 
process may be interrupted because a person dies of 
other causes. With screening, colorectal cancer may 
either be prevented (by the detection and removal of 
adenomas) or detected at an earlier stage with a more 
favourable prognosis. In this way, colorectal cancer 
incidence and/or colorectal cancer mortality may be 
reduced. The model also estimates harms associated 
with screening.
The quantification and model assumptions are 
described in detail in appendix 1. In brief, the age-
specific prevalence and multiplicity distribution of 
adenomas (the distribution of the individual number 
of adenomas across the population) were calibrated 
using autopsy studies.19-29 The duration of preclinical 
colorectal cancer (sojourn time) and the adenoma 
dwell-time (the duration of progression of adenomas) 
were calibrated using rates of interval cancers 
(cancers that are diagnosed between screening tests) 
and surveillance detected cancers (found during 
surveillance) in randomised gFOBT and sigmoidoscopy 
trials.8 30-35
For this study, we developed a MISCAN-Colon 
model version calibrated to the sex-, age-, stage-, and 
localisation-specific colorectal cancer incidence and 
survival as observed in Norway during the timeframe 
of the NORCCAP trial (1999-2011) (appendix 2 (fig 1)), 
using data provided by the Norwegian Cancer Registry.36 
Life expectancy was based on sex-specific lifetables for 
2007, the middle of the NORCCAP trial period, from 
Statistics Norway.37 We validated this model using 
the results of one of the trigger publications: 15-year 
follow-up data from the Norwegian Colorectal Cancer 
Prevention (NORCCAP) trial.5 The validation methods 
and results are described in appendix 3.
simulated cohorts
We simulated seven population cohorts consisting 
of men and women aged 50-79 years with a 15-year 
colorectal cancer risk varying from 1% to 7%, using the 
same Norwegian sex-specific MISCAN-Colon versions 
as we used for the validation. The age-specific onset of 
adenomas in MISCAN-Colon for all ages was adjusted 
to match the 15-year colorectal cancer risk in the 
seven cohorts. The modelled risk levels were chosen to 
cover the majority of individuals under consideration 
for this study (healthy people aged 50 to 79 years), 
but still with a manageable number of risk levels. We 
used the range of risk levels found when applying 
the QCancer risk prediction model to the UK Biobank 
cohort as guidance.38 The simulated risk levels from 
1% to 7% cover approximately 90% of the colorectal 
cancer risk levels found in the UK Biobank cohort 
(personal communication UK Biobank researcher 
Juliet Usher-Smith). We confirmed that the chosen risk 
levels also cover the range of risk levels observed in 
the general population, by comparing the risk levels 
with the 15 year colorectal cancer risk ranges found 
in two large population based cancer databases.39 40 
Data from the UK Biobank were also used to validate 
the QCancer prediction model for colorectal cancer. 
The QCancer Calculator is an open-access online tool 
that aims to predict individual colorectal cancer risk 
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based on risk factors such as medical history, lifestyle 
factors, and ethnicity.41 Individuals may predict their 
15-year colorectal cancer risk with this calculator 
(https://qcancer.org/15yr/colorectal/index.php). 
Subsequently, they may use this predicted colorectal 
cancer risk to look up the best risk-matching MISCAN-
Colon predictions of screening outcomes, to get a 
personal estimate of the magnitude of benefits and 
harms of colorectal cancer screening. The clinical 
practice guideline presents relevant details.15
screening strategies
For each cohort, we assessed four colorectal cancer 
screening strategies during a 15-year period: 
biennial FIT, annual FIT, a single sigmoidoscopy, 
and colonoscopy. All strategies were compared 
with no screening. For FIT, we chose a cut-off of 
20 µg Hb/g faeces since this is used in many screening 
programmes.42 We assumed that individuals with a 
positive FIT result and those with at least one adenoma 
(of any size) diagnosed at sigmoidoscopy screening 
were referred for colonoscopy.
Sensitivity and specificity of the screening tests were 
based on diagnostic test accuracy studies (table 1).43 47 
Age-specific risks for complications associated with 
colonoscopy were derived from SEER-Medicare data 
(table 1).45 48 49 Only complications requiring hospital 
admission within 30 days after the colonoscopy 
were taken into account. Only colonoscopies with 
polypectomies were considered to cause adverse 
effects. We included colorectal perforations and 
bleedings, other gastrointestinal adverse events, 
cardiovascular adverse events, and mortality related to 
screening procedure. The number of complications was 
calculated by multiplying the number of colonoscopies 
with polypectomies by each complication risk. The 
simulated cohorts were assumed to have no prior 
screening.
We simulated surveillance consistent with European 
Society of Gastrointestinal Endoscopy Guidelines.50 
Individuals with low risk findings (fewer than three 
low risk adenomas (<10 mm diameter) at primary 
screening) did not receive any surveillance, whereas 
individuals with high risk findings were offered 
surveillance with colonoscopy after three years, and 
thereafter colonoscopies repeated at intervals of three 
to five years depending on the findings.
As our aim is to provide individuals who are 
considering screening with estimates of the possible 
benefits and harms of participation, we assumed 100% 
adherence to screening, follow-up and surveillance for 
all analyses.
Outcomes
We distinguished the three screening-related outcome 
groups for the 15-year follow-up time frame chosen 
by the BMJ Rapid Recommendation guideline panel: 
benefits of screening, screening harms, and screening 
burden. For benefits of screening, we present model-
predicted colorectal cancer incidence and mortality, 
and all-cause mortality reduction. For screening 
burden, we present the number of screening tests, 
number of individuals with at least one colonoscopy 
(including screening colonoscopies), and number 
of individuals with at least two colonoscopies (for 
example, individuals with at least one surveillance 
colonoscopy). For screening harms, we present risk 
of screening related colorectal perforations and 
bleedings, other gastrointestinal adverse events, 
cardiovascular adverse events, and mortality related to 
screening procedure.
sensitivity analyses
As a one-way sensitivity analysis, we assessed results 
stratified by age and sex; and we assessed outcomes 
with lifetime follow-up instead of a 15-year follow-up.
certainty of evidence
We used the GRADE approach to address the certainty 
of the evidence.51 GRADE has not yet produced 
detailed guidance for assessing certainty of evidence 
in modelling studies. To make our assessment, we 
considered uncertainty associated with key inputs into 
the model.
guideline panel and patient involvement
According to the BMJ Rapid Recommendations process, 
a multiprofessional guideline panel that included 
three patients who have experienced colorectal 
cancer screening provided oversight to the study and 
identified the population and outcomes of interest.
results
The Rapid Recommendation panel suggests against 
screening if the risk is below a 15-year colorectal cancer 
risk of 3% and suggests screening if the risk is above 
3%.15 For simplification, we only describe the estimates 
for individuals with the 3% risk level. Estimates for all 
other risk levels are provided in table 2 and figure 1.
benefits of screening
MISCAN-Colon predicted that all screening strategies 
reduced colorectal cancer incidence and mortality 
box 1: linked resources for this bmj rapid recommendations cluster
•	Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal 
immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. 
BMJ 2019;367:l5515.15
•	Summary of the results from the Rapid Recommendation process
•	Jodal HC, Helsingen LM, Anderson JC, et al. Colorectal cancer screening with faecal 
testing, sigmoidoscopy or colonoscopy: a systematic review and network meta-
analysis. BMJ Open 2019;0:e032773.16
•	Review of all available trials that assessed colorectal cancer screening
•	Buskermolen M, Cenin DR, Helsingen LM, et al. Colorectal cancer screening with 
faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation 
modelling study. BMJ 2019;367:l5383.
•	Modelling study of different modalities for colorectal cancer screening
•	MAGICApp (http://magicproject.org/190220dist)
•	Expanded version of the results with evidence summaries and decision aids for use 
on all devices
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across all colorectal cancer risk groups (fig 1a and b, 
table 2). Colonoscopy showed the largest reduction 
in colorectal cancer mortality, but the differences 
between the screening strategies were small and 
the reduction may be similar for all strategies. For 
instance, the model predicted that, at 3% risk without 
screening, colorectal cancer mortality was nine deaths 
per 1000 individuals. There were six per 1000 fewer 
colorectal cancer deaths with colonoscopy and annual 
FIT (approximately 60% reduction) and five per 1000 
fewer deaths with sigmoidoscopy and biennial FIT 
(approximately 50% reduction).
table 1 | Key modelling assumptions used in study
input parameter base-case assumption references
Demography
All-cause mortality Norwegian lifetables 2007 Statistics Norway
natural course of cancer
Adenoma onset Age dependent (non-homogeneous Poisson) *
Adenoma progression:
 State transitions Age dependent *
 State duration (years, total) Exp(λ=130) *
Cancer progression (preclinical):
 Stage transitions Age-dependent *
 Stage durations (years) Exp (λ=2.5) *
Colorectal cancer incidence (without exposure to screening) Age-, stage-, and location-dependent Norwegian Cancer Registry
Colorectal cancer stage distribution Age- and location-dependent Norwegian Cancer Registry
Colorectal cancer survival Age-, stage-, and location-dependent Norwegian Cancer Registry
colonoscopy quality
Sensitivity (%)†:
 Adenomas 0-5 mm 75% *
 Adenomas 6-9 mm 85% *, van Rijn et al43
 Adenomas ≥10 mm 95% *, van Rijn et al43
 Malignant neoplasia 95% *
Specificity (%) 100%
Complete colonoscopy examination (%)‡ Men 93.5%, women 85.2% Holme et al44
Complication rates (%)§:
 With polypectomy Age dependent (50-79 years) van Hees et al45
  Perforations and bleeding 0.2-0.9
  Other GI adverse events 0.2-0.8
  Cardiovascular events 0.1-0.7
  Screening procedure related mortality 0.008-0.04
 Without polypectomy§ -
sigmoidoscopy quality
Sensitivity (%)†:
 Adenomas 0-5 mm 75% *
 Adenomas 6-9 mm 85% *, van Rijn et al43
 Adenomas ≥10 mm 95% *, van Rijn et al43
 Malignant neoplasia 95% *
Specificity (%)¶ 98.2% Buskermolen et al46
Complete examination (%)** Men 93.2%, women 83.8% Holme et al44
Faecel immunochemical test (Fit) quality
Sensitivity (%)†: Imperiale et al47
 Adenomas 0-5 mm 0
 Adenomas 6-9 mm 11.4
 Adenomas ≥10 mm 15.9
 Malignant neoplasia:
  Short before clinical detection 88.6
  Long before clinical detection 62.6
Specificity (%)¶ 97.6
Poisson=Poisson distribution; Exp=exponential distribution. GI=gastrointestinal.
*More details available in appendix 1.
†Sensitivity was defined as the probability of detecting an adenoma that was present at the time of test.
‡Colonoscopy was considered complete if the caecum was reached. In the incomplete examinations, the endpoint was assumed to be distributed 
uniformly over the colon/rectum.
§We assumed that colonoscopy without polypectomy was not associated with a higher risk of complications. The risk of complications for polypectomy 
was assumed to increase exponentially with age. Perforation and bleeding concerned adverse events requiring blood transfusions; other GI adverse 
events included paralytic ileus, nausea, vomiting and dehydration, abdominal pain; and cardiovascular adverse events included myocardial infarction or 
angina, arrhythmias, congestive heart failure, cardiac or respiratory arrest, or syncope, hypotension, or shock. The screening procedure related mortality 
was derived from estimates of the incidence of perforation and case-fatality for perforation.45 48 49
¶The lack of specificity indicates how many of the tests that did not detect adenomatous lesions resulted in a referral for follow-up colonoscopy. The 
MISCAN-Colon model is a natural history microsimulation model simulating onset of adenomas in some individuals, that may progress to colorectal 
cancer in some cases. The model does not explicitly simulate the presence of blood in stool. To simulate FIT screening, we rather use estimates of per-
person sensitivity and specificity by disease status based on a study by Imperiale et al. with a cut-off of 20 μg of haemoglobin per g of faeces.47 We fitted 
per-lesion sensitivity and per-person specificity of the model to the per-person sensitivity and specificity estimates found in the study. In the model, the 
probability for a person to test positive depends on the lack of specificity and the per-lesion sensitivity for the lesions present in that individual.
**Flexible sigmoidoscopy was considered complete if the junction of the sigmoid/colon descendens was reached. In the incomplete examinations, the 
endpoint was assumed to be distributed uniformly over the rectosigmoid.
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Colonoscopy may be the most effective strategy 
in reducing colorectal cancer incidence, followed by 
sigmoidoscopy (fig 1b, table 2). Colonoscopy was 
estimated to reduce colorectal cancer incidence by 10 
colorectal cancer cases and sigmoidoscopy by eight 
per 1000 individuals (approximately 30% reduction); 
annual FIT had four and biennial FIT had one incident 
cancer cases per 1000 screened (approximately 10% and 
5% reduction).
The estimated relative effects were similar across 
the different levels of baseline risk (1% to 7% over 
15 years) for both colorectal cancer incidence 
and mortality, resulting in larger absolute effects 
for colorectal cancer incidence and mortality for 
individuals with higher risk. The model assumes 
that prevented colorectal cancer deaths lead to a 
corresponding reduction in all-cause mortality. 
At 3% risk, the estimated relative reduction in 
all-cause mortality was around 1.5% (table 2), 
corresponding to a reduction of five per 1000 
individuals (all-cause mortality reduced from 328 
to 323).
table 2 | Predictions of benefits and harms of screening for individuals aged 50-79 years at varying levels of colorectal cancer risk. all outcomes are 
given per 1000 screened individuals over 15 years and compared to a scenario with no screening.
screening 
strategy
colorectal cancer
all-cause 
mortality 
reduction 
(%)
no of 
screening 
tests
no of  
individuals 
with ≥1  
colonoscopy
no of individ-
uals with ≥2 
colonoscopies
risk of complications
incidence 
reduction  
(%)
no of 
cases  
prevented
mortality  
reduction  
(%)
no of 
deaths 
prevented
Perforation 
and  
bleeding
Other 
gi 
events
cardio- 
vascular 
events
screen 
procedure 
related 
mortality
1% colorectal cancer risk without screening (10 cases per 1000, with risk of dying of colorectal cancer of 0.3% (3 per 1000))
Biennial FIT 8 1 53 2 0.4 5441 160 26 0.3 0.3 0.3 0.02
Annual FIT 18 2 62 2 0.5 9464 254 31 0.4 0.4 0.3 0.02
Single  
sigmoidoscopy
29 3 57 2 0.4 1000 82 28 0.4 0.4 0.3 0.02
Single  
colonoscopy
35 3 66 2 0.5 1000 1000 33 0.5 0.5 0.4 0.03
2% colorectal cancer risk without screening (20 cases per 1000, with risk of dying of colorectal cancer of 0.6% (6 per 1000))
Biennial FIT 6 1 51 3 0.8 5288 203 54 0.7 0.7 0.5 0.04
Annual FIT 16 3 60 4 0.9 9091 300 66 0.9 0.9 0.6 0.05
Single  
sigmoidoscopy
28 6 54 3 0.8 1000 159 57 0.8 0.8 0.6 0.05
Single  
colonoscopy
34 7 64 4 0.9 1000 1000 68 1.1 1.1 0.8 0.07
3% colorectal cancer risk without screening (30 cases per 1000, with risk of dying of colorectal cancer of 0.9% (9 per 1000))
Biennial FIT 5 1 50 5 1.1 5134 246 83 1.1 1 0.8 0.06
Annual FIT 15 4 59 6 1.3 8715 347 101 1.3 1.3 1 0.08
Single  
sigmoidoscopy
27 8 52 5 1.1 1000 237 86 1.3 1.2 0.9 0.07
Single  
colonoscopy
34 10 63 6 1.4 1000 1000 105 1.7 1.7 1.2 0.1
4% colorectal cancer risk without screening (40 cases per 1000, with risk of dying of colorectal cancer of 1.2% (12 per 1000))
Biennial FIT 4 2 49 6 1.5 4980 288 112 1.4 1.4 1.1 0.09
Annual FIT 15 6 59 7 1.8 8346 391 138 1.8 1.7 1.3 0.11
Single  
sigmoidoscopy
27 11 52 6 1.5 1000 312 119 1.7 1.7 1.2 0.1
Single  
colonoscopy
34 14 63 8 1.8 1000 1000 144 2.3 2.3 1.7 0.14
5% colorectal cancer risk without screening (50 cases per 1000, with risk of dying of colorectal cancer of 1.6% (16 per 1000))
Biennial FIT 4 2 49 8 1.8 4834 328 142 1.8 1.8 1.3 0.11
Annual FIT 15 7 59 9 2.2 7996 433 175 2.2 2.2 1.6 0.13
Single  
sigmoidoscopy
27 14 52 8 1.8 1000 382 153 2.2 2.1 1.6 0.13
Single  
colonoscopy
34 17 63 10 2.4 1000 1000 184 2.9 2.8 2.1 0.17
6% colorectal cancer risk without screening (60 cases per 1000, with risk of dying of colorectal cancer of 1.9% (19 per 1000))
Biennial FIT 5 3 50 9 2.2 4694 365 171 2.2 2.1 1.6 0.13
Annual FIT 15 9 59 11 2.6 7664 472 211 2.7 2.6 2 0.16
Single  
sigmoidoscopy
28 17 53 10 2.2 1000 446 189 2.7 2.6 1.9 0.16
Single  
colonoscopy
34 21 64 12 2.8 1000 1000 226 3.5 3.4 2.5 0.2
7% colorectal cancer risk without screening (70 cases per 1000, with risk of dying of colorectal cancer of 2.2% (22 per 1000))
Biennial FIT 5 4 50 11 2.6 4558 401 201 2.6 2.5 1.9 0.15
Annual FIT 16 11 59 13 3.0 7346 509 247 3.1 3.1 2.3 0.18
Single  
sigmoidoscopy
29 20 54 12 2.6 1000 505 228 3.2 3.1 2.3 0.19
Single  
colonoscopy
35 24 64 14 3.2 1000 1000 268 4 3.9 2.9 0.24
FIT=faecal immunochemical test.
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a. No of colorectal cancer deaths prevented per 1000 individuals
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Fig 1 | miscan-colon predictions of colorectal cancer mortality and incidence reduction, screen tests, colonoscopies and complications per 1000 
individuals, using biennial or annual faecal immunochemical test (Fit), flexible sigmoidoscopy, or colonoscopy. results are stratified by colorectal 
cancer risk. individuals were followed-up for 15 years
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screening burden
The two FIT strategies required the most screening 
tests (fig 1c, table 2). The number of FIT rounds for 
the simulated cohort depended on the age of the 
individual at the first screening and the screening 
interval. Individuals ≤65 years old at cohort entry 
received seven rounds with biennial FIT and 15 
rounds with annual FIT. However, many individuals 
received fewer screening rounds: individuals >65 
years at cohort entry because they stopped screening 
after age 79; individuals who died within 15 years 
of follow-up; individuals who tested FIT positive 
and were referred for a colonoscopy and therefore 
received screening according to the surveillance 
guidelines. For individuals with a 3% colorectal 
cancer risk, we predicted that approximately 8700 
tests were required with annual FIT screening, and 
5100 with biennial FIT screening. Colonoscopy 
screening resulted in the highest number of 
individuals receiving at least one colonoscopy, since 
all individuals received colonoscopy as a screening 
test (fig 1d, table 2). The number of individuals with 
at least two colonoscopies (that is, individuals with 
at least one surveillance colonoscopy) was highest 
for colonoscopy regardless of colorectal cancer risk 
(table 2).
screening harms
The risk of screening related mortality, colorectal 
perforations and bleedings, other serious gastro-
intestinal adverse events, or cardiovascular adverse 
events was proportional to the number of required 
colonoscopies (fig 1e-g). In the 3% colorectal cancer 
risk group, the predicted overall complication risk was 
lowest with biennial FIT screening (2.9 per 1000) and 
highest with colonoscopy screening (4.6 per 1000) 
(table 2).
sensitivity analyses
The model predicted similar reductions in cancer 
incidence and mortality for the screening tests for men 
and women for all levels of 15-year baseline risk of 
colorectal cancer, except for sigmoidoscopy, for which 
the model predicted that women may benefit slightly 
less than men (appendix 4 (tables 1-12, fig 1)).
When results were stratified by age, annual FIT was 
more effective in reducing colorectal cancer mortality 
than a single colonoscopy in younger individuals 
(50-59 years old). In older individuals (75-79 years), 
colonoscopy and sigmoidoscopy were more effective. In 
addition, the estimated risk of complications increased 
more with age for the colonoscopy and sigmoidoscopy 
screening strategies than for the FIT strategies, 
although the increase in risk in absolute numbers was 
small (appendix 4 (tables 1-12. fig 2)). For example, at 
3% colorectal cancer risk, a single colonoscopy strategy 
resulted in colorectal perforations and bleedings of 1.6 
per 1000 in men aged 50-54 years and 3.4 per 1000 in 
men aged 75-79 years.
When we considered lifetime follow-up, the model 
predicted larger absolute reductions in colorectal 
cancer incidence and mortality for all screening 
strategies (appendix 5 (figs 1 and 2)), and less 
differences between annual FIT and colonoscopy. 
At younger ages (50-64 years) the model predicted 
that annual FIT was more effective at reducing 
colorectal cancer incidence and mortality than a single 
colonoscopy, although the difference was small. For 
example, annual FIT screening prevented 43 lifetime 
colorectal cancer cases in those aged 50-54 compared 
with 37 prevented cases with a single colonoscopy.
certainty of evidence
We noted appreciable uncertainty associated with 
the following model inputs: (a) all colorectal cancers 
develop through adenomas; (b) differences in 
colorectal cancer risk are caused by differences in 
adenoma incidence; and (c) adenoma dwell time. 
There is no high certainty data to inform the model 
regarding these model inputs. Therefore, despite the 
predictive and external validity of the model against 
the NORCCAP study (appendix 3), the panel considered 
all model estimates as low certainty evidence.
discussion
Our microsimulation model analysis suggests that all 
screening strategies reduce colorectal cancer mortality 
during 15 years of follow-up, and colonoscopy, 
sigmoidoscopy, and annual FIT may also reduce 
colorectal cancer incidence. The extent of absolute 
risk reduction varies with baseline colorectal cancer 
risk. Few differences were observed when results 
were stratified by sex. When outcomes were stratified 
by age, we observed that FIT screening strategies 
were estimated to be more effective in younger 
individuals, while colonoscopy and sigmoidoscopy 
were more effective in older individuals. FIT screening 
strategies required the highest overall number of 
screening tests, and colonoscopy screening resulted 
in the highest number of colonoscopies, regardless of 
colorectal cancer risk. Consequently, we observed the 
highest probability of experiencing a complication in 
individuals who underwent screening with a single 
colonoscopy, with increasing risk in older age groups.
Colonoscopy may result in the largest reduction 
in colorectal cancer incidence, followed by sig-
moidoscopy and annual FIT. However, this finding 
was sensitive to the follow-up setting defined by the 
guideline panel. The panel chose a 15 year follow-
up period because this allowed model predictions to 
be validated against trial data. With lifetime follow-
up, the model predicted that relative incidence and 
mortality reductions from screening would persist for 
some more years, resulting in larger absolute numbers 
of prevented colorectal cancer cases and deaths. This 
was especially true for FIT, where lifetime follow-up 
resulted in higher estimates for colorectal cancer 
incidence reductions, making the test comparable to 
colonoscopy. However, because longer term follow-
up data from trials are lacking, lifetime estimates are 
more uncertain and were thus not taken into account 
by the panel.
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strengths and limitations of this study
Model predictions for colorectal cancer mortality and 
incidence reduction in this study are considerably 
higher than those observed in randomised screening 
trials. These seemingly discrepant results can be 
explained by our assumption of 100% adherence 
to screening tests, work-up, and surveillance 
colonoscopies, whereas trial outcomes are the 
result of real-world adherence patterns, which are 
considerably lower. When we replicated the NORCCAP 
trial population including observed adherence 
patterns, MISCAN-Colon predictions for colorectal 
cancer incidence and mortality reduction were in line 
with the trial results (appendix 3). Moreover, when 
we replicated the design of an Italian cohort study, 
the model predicted reductions in colorectal cancer 
incidence and mortality resulting from FIT screening 
that aligned well with those results observed in that 
study (data not shown).52
We acknowledge that 100% adherence gives esti-
mates that are higher than what would be expected in 
a population screening programme, when adherence 
is never 100%. However, our intention was to inform 
individuals about expected effectiveness when they 
(fully) participate in screening rather than considering 
the impact of a screening programme from a public 
health perspective and assessing results at the 
population level. The aim of this study was to support 
the BMJ Rapid Recommendation panel by comparing 
different screening strategies, stratified by baseline 
15-year colorectal cancer risk, using microsimulation 
modelling. A strength of this work is that we validated 
our model using the recently published 15-year follow-
up results of the NORCCAP trial.5 To our knowledge, 
this is the first modelling study to enable individuals 
to directly link their individual colorectal cancer risk to 
their predicted benefits and harms of colorectal cancer 
screening. Individuals can do this through determining 
their colorectal cancer risk using a calculator, such as 
the QCancer calculator,41 incorporating information on 
age, sex, ethnicity, and other risk factors. The QCancer 
(10 year) calculator performed better than other 
prediction tools when externally validated against the 
UK Biobank cohort. However, like the other colorectal 
cancer risk prediction tools, it is far from perfect and, 
with an area under the curve of 0.67 in men and 0.65 
in women, it poorly discriminates between those at 
a lower and those at a higher risk, which may lead 
to misclassification of individual baseline colorectal 
cancer risk.16 53
Our study has several limitations. First, MISCAN-
Colon could not replicate the sex-specific differences 
in colorectal cancer incidence and mortality reduction 
as observed in the NORCCAP sigmoidoscopy screening 
trials16 (appendix 3 (table 1)), despite the sex-specific 
adjustments to the model.5 On the one hand, it may 
be that the dwell time of adenomas differs between 
men and women, potentially because the proportion 
of cancers in the proximal colon is higher in women. 
In MISCAN-Colon we did not assume sex-specific or 
localisation-specific differences in duration because of 
insufficient information from clinical studies or autopsy 
studies. On the other hand, the observed difference in 
screening effectiveness of sigmoidoscopy between men 
and women is higher in the NORCCAP trial than what 
was observed in the other sigmoidoscopy studies.16
Second, at the request of the guideline panel, we 
modelled only four screening strategies, and, for FIT, 
applied only one cut-off value (20 μg haemoglobin/g 
faeces). Applying lower or higher FIT cut-off values may 
result in higher or lower colorectal cancer screening 
effectiveness. In view of the results of diagnostic 
studies, there are also uncertainties regarding the 
additional benefit of using FIT annually instead of 
biennially.54
Third, it remains unknown whether differences in 
colorectal cancer risk among the population are caused 
by variations in the number of adenomas, a faster 
adenoma progression to malignancy, or a combination 
of the two. These variations may exist between men 
and women, different ethnicities, different levels of 
genetic predisposition or different environments. For 
this analysis, we assumed that differences in adenoma 
incidence cause differences in colorectal cancer risk.
Fourth, in MISCAN-Colon we assumed that all 
cancers developed from precursors via a common 
pathway. In the model description we refer to this 
as the adenoma carcinoma pathway with adenoma 
being the precursor lesions. However, recent evidence 
suggested that three distinct cancer pathways are 
relevant: about 60-70% of cancers develop via the 
conventional adenoma carcinoma sequence, 20-30% 
via the serrated polyp pathway, and 3% via the Lynch 
pathway.55 In the model, we calibrated the average 
time it takes for a precursor to develop into colorectal 
cancer. Therefore, all precursor types are included 
in the modelled mix of slow and rapid progressing 
lesions. Modelling one common pathway may have 
consequences for the modelled results. For instance, 
we may overestimate the effectiveness of FIT and 
sigmoidoscopy compared with colonoscopy. Evidence 
is accumulating that FIT might be less sensitive for 
serrated polyps, and these polyps are usually located 
in the right side of the colon.39 40 47 56 These polyps may 
have higher malignant potential than conventional 
adenomas. However, evidence for the malignant 
potential of the precursors from the distinct pathways 
is not yet decisive.
Fifth, this project focuses on the individual’s 
perspective rather than on the perspective of public 
health professionals deciding on population-based 
screening programmes, which was the reason for 
assuming 100% adherence to screening and follow-
up for all screening options. In population-based 
screening programmes, adherence rates of the 
various screening options can differ widely across 
countries.57-59 When public health professionals 
make decisions about population-based screening 
programmes, they should also include evidence on the 
country-specific adherence rate to determine which 
screening option is most suitable. In addition, cost 
effectiveness analysis should be performed. For public 
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health professionals, a message from this study still 
may lie in the finding that benefits of screening do not 
differ much between the screening options.
Sixth, the estimated reduction in all-cause mortality 
is not observed in large randomised trials of gFOBT 
and sigmoidoscopy screening, which have not shown 
a significant reduction of all-cause mortality with 
screening. The BMJ Rapid Recommendations panel 
did not regard all-cause mortality estimates from 
the model as clinically relevant when making their 
recommendations.
Finally, we did not model probability bands. An 
important strength of this study is the large number 
of simulations we have performed, with different 
screening strategies, background colorectal cancer 
risks, age groups, and sex. The drawback is that to 
obtain probability bands for all simulations in this 
article, would require 840 000 simulations, which is 
too computationally expensive.
Policy implications and conclusions
Notwithstanding the limitations, this modelling study 
addresses an important gap in current knowledge 
on colorectal cancer screening. There is insufficient 
evidence from clinical studies to determine which 
screening modality is most effective.13 Currently, 
three large randomised trials are under way to assess 
the comparative effectiveness of colonoscopy and 
FIT,60 and one on sigmoidoscopy versus FIT.53 Our 
results indicate that the difference in colorectal cancer 
mortality reduction between screening modalities is 
substantially smaller than the differences in colorectal 
cancer mortality between screening and no screening. 
To achieve sufficient power to demonstrate these 
differences, the current colorectal cancer screening 
trials would require very large sample sizes. It is 
therefore unlikely that a comparison of all evaluated 
strategies will ever become available from randomised 
trials. Comparing screening modalities stratified by 
baseline colorectal cancer risk, age, and sex is even 
more complicated. In these cases, clinicians and 
patients must make choices on the basis of the best 
available evidence, even if it is of low certainty.
Our belief is that our modelling results are genera-
lisable to individuals across the Western world. 
Although there may be some differences in life 
expectancy, age-specific colorectal cancer incidence, 
colorectal cancer stage distribution, and colorectal 
cancer survival compared with Norway, we expect that 
these differences do not significantly affect relative 
differences between screening modalities.
This study, together with the other publications in 
this BMJ Rapid Recommendations cluster, supports 
patients and physicians in the process of shared 
decision making by quantifying screening benefits, 
harms, and burdens on an individual level. For 
example, based on a certain colorectal cancer risk 
threshold, some low risk individuals may conclude that 
the undesirable consequences of screening outweigh 
the desirable consequences. Evaluating the modelling 
results, we predicted that lifetime follow-up of screened 
individuals resulted in different estimates of screening 
effectiveness compared with 15 year follow-up. This 
additional finding encourages researchers to continue 
the follow-up in their randomised cohorts to evaluate 
longer term benefits of screening.
In conclusion, MISCAN-Colon predicted that 
all screening modalities reduce colorectal cancer 
mortality during a 15 year follow-up period, regardless 
of colorectal cancer risk, age, and sex. A single 
colonoscopy may be the most effective screening 
modality in preventing colorectal cancer incidence 
during 15 years follow-up. Colonoscopy screening is 
also associated with the highest risk for complications, 
but overall complication risks are low for colorectal 
screening. These results will contribute to risk-based 
colorectal cancer screening recommendations in this 
BMJ Rapid Recommendation project.15
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